Overview

Efficacy and Safety of the Combination Vitamin D With Standard of Care in Egyptian Patients With Untreated Chronic Hepatitis C

Status:
Withdrawn

Trial end date:
2014-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to show the superiority of a 4 weeks lead-in phase of Vitamin D followed by a 48 weeks combination of Vitamin D with PEG-IFN plus RBV in comparison with standard PEG-IFN + RBV in untreated Egyptian patients with chronic hepatitis C, on the sustained virological response (SVR) at 3 months after end of treatment (week 60).

Phase:

Phase 3

Details

Lead Sponsor:

ANRS, Emerging Infectious Diseases
French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)

Collaborator:

Institut Pasteur

Treatments:

Ergocalciferols
Interferon alpha-2
Interferon-alpha
Interferons
Peginterferon alfa-2b
Ribavirin
Vitamin D
Vitamins